Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

Drug Dosing: Infants and Children

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism.

Blood advances·2026

Same author

Impact of Adolescent and Young Adult Cancer Expertise in Oncologists on AYA Outcomes in Hodgkin Lymphoma: A Population-Based Study in Ontario, Canada.

Cancer medicine·2026

Same author

Role of the perinatal experience on the risk of acute leukemia in childhood or adolescence: Systematic review and meta-analysis.

International journal of cancer·2025

Same author

Central Adiposity and Visceral Fat in Long-Term Survivors of Acute Lymphoblastic Leukemia in Childhood and Adolescence: Exploration of an Underappreciated Risk.

Pediatric blood & cancer·2025

Same author

Effective nutritional intervention improves the health-related quality of life (HRQL) of undernourished children with cancer: results of a randomized, controlled phase 3 trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025

Same author

Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis.

Blood advances·2025

Search research articles

Related Experiment Video

Updated: May 13, 2026

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

Essential medicines for pediatric oncology in developing countries.

Parth S Mehta¹, John T Wiernikowski, J A Sergio Petrilli

¹Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77094, USA. psmehta@txch.org

Pediatric Blood & Cancer

|March 2, 2013

Summary

Improving childhood cancer survival in low and middle income countries (LMICs) requires essential chemotherapy drugs. A proposed list of 51 drugs aims to enhance treatment and save young lives.

More Related Videos

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

Related Experiment Videos

Last Updated: May 13, 2026

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

Area of Science:

Pediatric Oncology
Global Health
Pharmacology

Background:

Childhood cancer poses a significant global health burden, disproportionately affecting low and middle income countries (LMICs).
Survival rates for pediatric cancers are markedly lower in LMICs compared to high-income nations, highlighting a critical disparity in care.
Limited access to safe and affordable chemotherapy is a primary obstacle to improving outcomes for children with cancer in these regions.

Purpose of the Study:

To identify and propose a list of essential medications crucial for improving the survival rates of children diagnosed with cancer in LMICs.
To address the challenge of chemotherapy drug availability by recommending a core set of cost-effective treatments.

Main Methods:

A comprehensive review and selection process was undertaken to identify essential drugs.
The proposed list includes chemotherapeutics, infectious disease agents, and supportive care medications vital for pediatric cancer treatment.

Main Results:

A list of 51 essential drugs has been identified as critical for enhancing pediatric cancer survival in LMICs.
An additional 13 drugs were recognized for their significant value in further supporting treatment efficacy and patient care.

Conclusions:

The availability of a curated list of essential medicines is paramount to bridging the survival gap for childhood cancer patients in LMICs.
Implementing access to these recommended drugs can substantially improve treatment outcomes and reduce mortality in resource-limited settings.